Drug intelligence / Profile preview

sparc-147609

Development stage: Phase 1
Lead developer: SPARC
Modality: Small Molecules
Administration: Intravenous

Overview

sparc-147609 is an investigational intravenous small molecule developed by Sun Pharma for the treatment of ovarian carcinoma. Its precise mechanism of action has not been disclosed. The drug reached Phase 1 clinical trials for ovarian cancer, but there are no reports of approval or further development beyond this stage[2][4]. It is not approved in any country and has no known brand names or reported adverse events.

Beyond the preview

Go deeper on sparc-147609.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sparc-147609.

Explore the full profile